Fig. 3: Progression-free survival in the intention-to-treat population.

a Kaplan–Meier estimates by treatment group. b Estimated hazard ratios (HRs) and 95% CIs from the stratified univariable Cox models in four groups. c Kaplan–Meier estimates by radiation type (ENI vs CFI). d Kaplan–Meier estimates by erlotinib administration (with erlotinib vs without erlotinib).